Compare Inovio Pharmaceuticals Inc (INO) vs Palo Alto Networks Inc (PANW) Price & Performance

INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.

Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.

Palo Alto Networks (PANW) trades at $353.85, down 1.35% on the day but showing strong bullish momentum with shares roughly doubling over three months. The stock exhibits robust fundamentals with consistent earnings beats, revenue growth to $9.22B in 2025, and a high gross margin of 71.94%. Technical indicators signal a bullish trend, supported by positive moving averages, though RSI levels suggest potential overbought conditions near-term.

Outlook remains positive driven by AI-driven cybersecurity demand and platformization strategy, but high valuation ratios (P/E 311.9, P/S 24.9) pose risks. Analyst consensus is strongly bullish (74% Buy ratings) with a $339.56 price target, though competition and integration costs are key watchpoints for investors.